(Q34507672)

English

Insulin glargine

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

Insulin glargine. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

author name string

Campbell RK

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

White JR

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Levien T

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Baker D

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

1 December 2001

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1938-57; discussion 1923

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Improving insulin therapy: achievements and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin analogues: new agents for improving glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nocturnal blood glucose control in type I diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology of human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin analogues and their potential in the management of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of insulin glargine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980148-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(01)80148-X

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34507672&oldid=1563392664"